Current Report Filing (8-k)
January 04 2018 - 5:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 3, 2018
ATARA BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36548
|
|
46-0920988
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Atara Biotherapeutics, Inc.
611 Gateway Boulevard, Suite 900
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650)
278-8930
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On January 3, 2018, Atara Biotherapeutics, Inc. (Atara or the Company) entered into an underwriting agreement, or
the Underwriting Agreement, with J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein, collectively, the Underwriters, relating to the public offering, issuance and sale of 7,000,000
shares of the Companys common stock, par value $0.0001 per share, or the Common Stock. The price to the public in this offering is $18.25 per share, and the Underwriters have agreed to purchase the shares from the Company pursuant to the
Underwriting Agreement at a price of $17.155 per share. Under the terms of the Underwriting Agreement, Atara also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,050,000 shares of Common Stock at the
public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from this offering are expected to be approximately $127,750,000, before deducting underwriting discounts and commissions and other estimated
offering expenses payable by the Company, or $146,912,500 if the Underwriters exercise in full their option to purchase additional shares of Common Stock. The offering is expected to close on January 8, 2018, subject to customary closing
conditions.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions
to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and
covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting
parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement.
The offering is being made pursuant to the Companys effective registration statement on Form
S-3
and an accompanying prospectus (Registration Statement
No. 333-207876)
previously filed with the SEC and a preliminary and final prospectus supplement thereunder. The Underwriting Agreement is filed as
Exhibit 1.1 to this report, and the description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of
the shares in the offering is attached as Exhibit 5.1 hereto.
Additionally, the Company is filing information for the purpose of updating
the risk factor disclosure contained in its prior public filings, including those discussed under the heading Item 1A. Risk Factors in its Quarterly Report on Form
10-Q
for the quarter ended
September 30, 2017, filed with the SEC on November 9, 2017. The Company is also supplementing and updating certain aspects of the description of its business from that described under the heading Item 1. Business in its Annual
Report on Form
10-K
for the year ended December 31, 2016, filed with the SEC on March 9, 2017. The updated Company disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Atara Biotherapeutics, Inc.
|
|
|
|
Dated: January 4, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John McGrath
|
|
|
|
|
|
|
John McGrath
|
|
|
|
|
|
|
Chief Financial Officer
|
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024